Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Descartes-08 by Cartesian Therapeutics for Systemic Lupus Erythematosus: Likelihood of Approval
Descartes-08 is under clinical development by Cartesian Therapeutics and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData,...
Descartes-08 by Cartesian Therapeutics for Myasthenia Gravis: Likelihood of Approval
Descartes-08 is under clinical development by Cartesian Therapeutics and currently in Phase II for Myasthenia Gravis. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Cartesian Therapeutics's Descartes-08?
Descartes-08 is a gene-modified cell therapy commercialized by Cartesian Therapeutics, with a leading Phase II program in Myasthenia Gravis. According...